- Home
- GNS vs IGC Comparison
GNS vs IGC Comparison
Compare GNS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- IGC
- Stock Information
- Founded
- GNS 2002
- IGC 2005
- Country
- GNS Singapore
- IGC United States
- Employees
- GNS N/A
- IGC N/A
- Industry
- GNS Other Consumer Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- GNS Real Estate
- IGC Health Care
- Exchange
- GNS Nasdaq
- IGC Nasdaq
- Market Cap
- GNS 17.8M
- IGC 20.2M
- IPO Year
- GNS 2022
- IGC N/A
- Fundamental
- Price
- GNS $1.32
- IGC $0.31
- Analyst Decision
- GNS
- IGC Strong Buy
- Analyst Count
- GNS 0
- IGC 2
- Target Price
- GNS N/A
- IGC $3.88
- AVG Volume (30 Days)
- GNS 13.0M
- IGC 246.3K
- Earning Date
- GNS 04-30-2025
- IGC 06-27-2025
- Dividend Yield
- GNS N/A
- IGC N/A
- EPS Growth
- GNS N/A
- IGC N/A
- EPS
- GNS N/A
- IGC N/A
- Revenue
- GNS $7,912,718.00
- IGC $1,271,000.00
- Revenue This Year
- GNS $233.65
- IGC $15.26
- Revenue Next Year
- GNS $570.20
- IGC $3.41
- P/E Ratio
- GNS N/A
- IGC N/A
- Revenue Growth
- GNS N/A
- IGC N/A
- 52 Week Low
- GNS $0.21
- IGC $0.25
- 52 Week High
- GNS $3.20
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- GNS 89.26
- IGC 52.79
- Support Level
- GNS $0.34
- IGC $0.30
- Resistance Level
- GNS $0.71
- IGC $0.32
- Average True Range (ATR)
- GNS 0.14
- IGC 0.01
- MACD
- GNS 0.07
- IGC 0.00
- Stochastic Oscillator
- GNS 83.51
- IGC 33.33
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.